Terminated PHASE3 INTERVENTIONAL 4-arm NCT05092360

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Sponsor: Merck Sharp & Dohme LLC

Conditions Fallopian Tube Cancer Platinum-resistant Ovarian Cancer Primary Peritoneal Cancer

Interventions Gemcitabine Nemvaleukin Nemvaleukin and Pembrolizumab Combination Paclitaxel Pegylated Liposomal Doxorubicin (PLD) Pembrolizumab Topotecan

Updated 19 times since 2021 Last updated: Aug 11, 2025 Started: Jan 10, 2022 Primary completion: Jan 8, 2025 Completion: May 8, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated due to business and strategic decision.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

A PHASE3 clinical study on Fallopian Tube Cancer and Platinum-resistant Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 19 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

19 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE3
Sep 2025 — Dec 2025 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Active Not Recruiting → Recruiting

▶ Show 14 earlier versions

Apr 2024 — May 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2023 — Apr 2024 [monthly]

Recruiting PHASE3
Jul 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Dec 2022 — Mar 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE3
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE3
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE3
Apr 2022 — Jun 2022 [monthly]

Recruiting PHASE3
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Mural Oncology, Inc

Data source: Mural Oncology, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Albany, United States , Albuquerque, United States , Anchorage, United States , Angers, France , Atlanta, United States , Austin, United States , Aviano, Italy , Baltimore, United States , Barcelona, Spain and 87 more locations